Table 3.

Univariate and multivariate analyses of overall survival

Univariate Analysis
	N	HR (95% CI)	p
Age (years)	60	1.04 (0.99-1.10)	0.16
PS 0	14	0.89 (0.32-2.44)	0.81
PS 1-2	46	1 Ref.
Male	36	1.09 (0.45-2.61)
Female	24	1 Ref.	0.85
Adenocarcinoma	39	1 Ref.
Non-adenocarcinoma	21	2.88 (1.21-6.87)	0.02
Smoker	22	0.96 (0.34-2.68)
Non-smoker	27	1 Ref.	0.93
EGFR mutated	9	1 Ref.
EGFR wild-type	41	1.19 (0.38-3.68)	0.77
K-ras mutated	10	0.81 (0.24-2.78)	0.73
K-ras wild-type	46	1 Ref.
Low BRCA1&AEG1 expression	18	1 Ref.
High BRCA1&AEG1 expression	17	2.80 (0.84-9.32)	0.10
Other combinations of BRCA1&AEG1 expression	25	1.84 (0.62-5.41)	0.27
1 treatment line	18	1 Ref.
≥ 2 treatment lines	42	0.44 (0.16-1.22)	0.12
1 metastatic site	30	1 Ref.
≥ 2 metastatic sites	24	1.46 (0.57-3.72)	0.43
Bone metastases	23	3.06 (1.15-8.16)	0.03
No bone metastases	31	1 Ref.
Brain metastases	10	1 Ref.
No brain metastases	44	1.86 (0.54-6.48)	0.33
Multivariate Analysis
Adenocarcinoma	36	1 Ref.
Non-adenocarcinoma	18	3.17 (1.21-8.31)	0.02
1 treatment line	14	7.22 (1.96-26.64)	0.003
≥ 2 treatment lines	40	1 Ref.
Bone metastases	23	4.73 (1.58-14.17)	0.005
No bone metastases	31	1 Ref.